Overview

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

Status:
Not yet recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
The TILE pilot study will be a multicenter, open-label, assessor-blinded RCT (randomized control trial) comparing extended LMWH (Low Molecular Weight Heparin) vs. DOAC (Direct Oral Anticoagulants) to PTS (prevent post thrombotic syndrome) in patients with DVT (Deep Vein Thrombosis).
Phase:
Phase 4
Details
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborators:
LEO Pharma
Sunnybrook Research Institute
Treatments:
Dalteparin
Heparin, Low-Molecular-Weight
Rivaroxaban
Tinzaparin